RU2488384C2 - Композиции для лечения неопластических заболеваний - Google Patents
Композиции для лечения неопластических заболеваний Download PDFInfo
- Publication number
- RU2488384C2 RU2488384C2 RU2010110658/15A RU2010110658A RU2488384C2 RU 2488384 C2 RU2488384 C2 RU 2488384C2 RU 2010110658/15 A RU2010110658/15 A RU 2010110658/15A RU 2010110658 A RU2010110658 A RU 2010110658A RU 2488384 C2 RU2488384 C2 RU 2488384C2
- Authority
- RU
- Russia
- Prior art keywords
- composition according
- taxane
- weight
- carrier
- pvp
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract 18
- 201000010099 disease Diseases 0.000 title claims abstract 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title claims abstract 3
- 230000001613 neoplastic effect Effects 0.000 title claims abstract 3
- 229940123237 Taxane Drugs 0.000 claims abstract 17
- DKPFODGZWDEEBT-QFIAKTPHSA-N taxane Chemical class C([C@]1(C)CCC[C@@H](C)[C@H]1C1)C[C@H]2[C@H](C)CC[C@@H]1C2(C)C DKPFODGZWDEEBT-QFIAKTPHSA-N 0.000 claims abstract 17
- 239000004094 surface-active agent Substances 0.000 claims abstract 6
- 238000000034 method Methods 0.000 claims abstract 5
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract 5
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 claims abstract 3
- 239000003814 drug Substances 0.000 claims abstract 3
- 239000007787 solid Substances 0.000 claims abstract 3
- 239000012052 hydrophilic carrier Substances 0.000 claims abstract 2
- 239000007962 solid dispersion Substances 0.000 claims abstract 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims 5
- 239000001267 polyvinylpyrrolidone Substances 0.000 claims 5
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims 5
- 238000004108 freeze drying Methods 0.000 claims 4
- 229920000858 Cyclodextrin Polymers 0.000 claims 2
- 208000009011 Cytochrome P-450 CYP3A Inhibitors Diseases 0.000 claims 2
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 claims 2
- 239000002202 Polyethylene glycol Substances 0.000 claims 2
- 239000004372 Polyvinyl alcohol Substances 0.000 claims 2
- -1 carboxymethyl ethyl Chemical group 0.000 claims 2
- 229920001223 polyethylene glycol Polymers 0.000 claims 2
- 229920002451 polyvinyl alcohol Polymers 0.000 claims 2
- 239000002904 solvent Substances 0.000 claims 2
- 229920000623 Cellulose acetate phthalate Polymers 0.000 claims 1
- 229920001661 Chitosan Polymers 0.000 claims 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 claims 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 claims 1
- 239000001856 Ethyl cellulose Substances 0.000 claims 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 claims 1
- 229930195725 Mannitol Natural products 0.000 claims 1
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 claims 1
- 229920003080 Povidone K 25 Polymers 0.000 claims 1
- 229920003081 Povidone K 30 Polymers 0.000 claims 1
- 229920003082 Povidone K 90 Polymers 0.000 claims 1
- NCDNCNXCDXHOMX-UHFFFAOYSA-N Ritonavir Natural products C=1C=CC=CC=1CC(NC(=O)OCC=1SC=NC=1)C(O)CC(CC=1C=CC=CC=1)NC(=O)C(C(C)C)NC(=O)N(C)CC1=CSC(C(C)C)=N1 NCDNCNXCDXHOMX-UHFFFAOYSA-N 0.000 claims 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims 1
- 229930006000 Sucrose Natural products 0.000 claims 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims 1
- 229940081734 cellulose acetate phthalate Drugs 0.000 claims 1
- 229920001577 copolymer Polymers 0.000 claims 1
- 229960000913 crospovidone Drugs 0.000 claims 1
- 229940097362 cyclodextrins Drugs 0.000 claims 1
- 239000008121 dextrose Substances 0.000 claims 1
- 229960003668 docetaxel Drugs 0.000 claims 1
- 229920001249 ethyl cellulose Polymers 0.000 claims 1
- 235000019325 ethyl cellulose Nutrition 0.000 claims 1
- 229960004667 ethyl cellulose Drugs 0.000 claims 1
- 238000001704 evaporation Methods 0.000 claims 1
- 229920001477 hydrophilic polymer Polymers 0.000 claims 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 claims 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 claims 1
- 229920003132 hydroxypropyl methylcellulose phthalate Polymers 0.000 claims 1
- 229940031704 hydroxypropyl methylcellulose phthalate Drugs 0.000 claims 1
- 239000000594 mannitol Substances 0.000 claims 1
- 235000010355 mannitol Nutrition 0.000 claims 1
- 229920000609 methyl cellulose Polymers 0.000 claims 1
- 239000001923 methylcellulose Substances 0.000 claims 1
- 235000010981 methylcellulose Nutrition 0.000 claims 1
- 229940100691 oral capsule Drugs 0.000 claims 1
- 229920000058 polyacrylate Polymers 0.000 claims 1
- 229920000642 polymer Polymers 0.000 claims 1
- 229920000193 polymethacrylate Polymers 0.000 claims 1
- 229920005862 polyol Polymers 0.000 claims 1
- 150000003077 polyols Chemical class 0.000 claims 1
- 229920002689 polyvinyl acetate Polymers 0.000 claims 1
- 239000011118 polyvinyl acetate Substances 0.000 claims 1
- 229920000523 polyvinylpolypyrrolidone Polymers 0.000 claims 1
- 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 claims 1
- 238000002360 preparation method Methods 0.000 claims 1
- NCDNCNXCDXHOMX-XGKFQTDJSA-N ritonavir Chemical group N([C@@H](C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC=1C=CC=CC=1)NC(=O)OCC=1SC=NC=1)CC=1C=CC=CC=1)C(=O)N(C)CC1=CSC(C(C)C)=N1 NCDNCNXCDXHOMX-XGKFQTDJSA-N 0.000 claims 1
- 229960000311 ritonavir Drugs 0.000 claims 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 claims 1
- 238000000935 solvent evaporation Methods 0.000 claims 1
- 239000000600 sorbitol Substances 0.000 claims 1
- 239000005720 sucrose Substances 0.000 claims 1
- 235000000346 sugar Nutrition 0.000 claims 1
- 150000008163 sugars Chemical class 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
- 238000004090 dissolution Methods 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 239000000126 substance Substances 0.000 abstract 1
Images
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US95776407P | 2007-08-24 | 2007-08-24 | |
| US60/957,764 | 2007-08-24 | ||
| GB0716591.3 | 2007-08-24 | ||
| GB0716591A GB0716591D0 (en) | 2007-08-24 | 2007-08-24 | Composition |
| PCT/GB2008/002854 WO2009027644A2 (en) | 2007-08-24 | 2008-08-22 | Composition |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| RU2010110658A RU2010110658A (ru) | 2011-09-27 |
| RU2488384C2 true RU2488384C2 (ru) | 2013-07-27 |
Family
ID=38599259
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2010110658/15A RU2488384C2 (ru) | 2007-08-24 | 2008-08-22 | Композиции для лечения неопластических заболеваний |
Country Status (5)
| Country | Link |
|---|---|
| JP (1) | JP5404625B2 (enExample) |
| CN (1) | CN101854919B (enExample) |
| ES (1) | ES2535401T3 (enExample) |
| GB (1) | GB0716591D0 (enExample) |
| RU (1) | RU2488384C2 (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR086913A1 (es) * | 2011-06-14 | 2014-01-29 | Novartis Ag | 4-metil-3-[[4-(3-piridinil)-2-pirimidinil]-amino]-n-[5-(4-metil-1h-imidazol-1-il)-3-(trifluoro-metil)-fenil]-benzamida amorfa, forma de dosificacion que la contiene y metodo para prepararlas |
| WO2015152433A1 (en) | 2014-03-31 | 2015-10-08 | Hanmi Pharm. Co., Ltd. | Amorphous solid dispersion comprising paclitaxel, tablet comprising the same, and method for preparing the same |
| CN105106420A (zh) * | 2015-07-30 | 2015-12-02 | 马衍福 | 一种抗肿瘤疾病中药制剂 |
| WO2018170196A1 (en) | 2017-03-15 | 2018-09-20 | Dfb Soria, Llc | Topical therapy for the treatment of skin malignancies using nanoparticles of taxanes |
| WO2019047812A1 (zh) | 2017-09-07 | 2019-03-14 | 深圳信立泰药业股份有限公司 | 多西他赛共缀物的药物组合物及制备方法 |
| EP3897610B1 (en) | 2018-12-21 | 2025-04-16 | Modra Pharmaceuticals B.V. | Cancer treatment using docetaxel by controlling peak plasma levels |
| PE20220129A1 (es) * | 2018-12-21 | 2022-01-27 | Modra Pharmaceuticals B V | Tratamiento de combinacion para tumores solidos usando docetaxel y un inhibidor de cyp3a |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2004012714A1 (en) * | 2002-08-05 | 2004-02-12 | Dsm Ip Assets B.V. | Oral dosage forms of water insoluble drugs and methods of making the same |
| WO2004050058A2 (en) * | 2002-11-29 | 2004-06-17 | Janssen Pharmaceutica N.V. | Pharmaceutical compositions comprising a basic respectively acidic drug compound, a surfactant and a physiologically tolerable water-soluble acid respectively base |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HK1048956B (zh) * | 1999-05-27 | 2006-07-28 | 阿库斯菲尔公司 | 多孔药物基质及其制造方法 |
| KR100508518B1 (ko) * | 2002-11-13 | 2005-08-17 | 한미약품 주식회사 | 초임계유체 공정을 이용한 파클리탁셀 고체분산체의 제조방법 및 이 방법으로 제조된 파클리탁셀 고체분산체 |
-
2007
- 2007-08-24 GB GB0716591A patent/GB0716591D0/en not_active Ceased
-
2008
- 2008-08-22 CN CN2008801042752A patent/CN101854919B/zh active Active
- 2008-08-22 JP JP2010521478A patent/JP5404625B2/ja active Active
- 2008-08-22 RU RU2010110658/15A patent/RU2488384C2/ru active
- 2008-08-22 ES ES08788414.4T patent/ES2535401T3/es active Active
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2004012714A1 (en) * | 2002-08-05 | 2004-02-12 | Dsm Ip Assets B.V. | Oral dosage forms of water insoluble drugs and methods of making the same |
| WO2004050058A2 (en) * | 2002-11-29 | 2004-06-17 | Janssen Pharmaceutica N.V. | Pharmaceutical compositions comprising a basic respectively acidic drug compound, a surfactant and a physiologically tolerable water-soluble acid respectively base |
Non-Patent Citations (1)
| Title |
|---|
| IKEZOE T. «HIV-1 protease inhibitor, ritonavir: A potent inhibitor of CYP3A4, enhanced the anticancer effects of docetaxel in androgen-independent prostate cancer cells in vitro and in vivo» // Cancer Research, 2004, p.7426-74316164 [онлайн]. [Найдено в Интернет 03.05.2012] <URL:http://www.ncbi.nlm.nih.gov/pubmed/15492266>. BARDELMEIJER H.A. «Low systemic exposure of oral docetaxel in mice resulting from extensive first-pass metabolism is boosted be rotonavir» // Cancer Research, 2002, p.6158-6164 [онлайн]. [Найдено в Интернет 03.05.2012] <URL:http://www.ncbi.nlm.nih.gov/pubmed/12414642 >. * |
Also Published As
| Publication number | Publication date |
|---|---|
| ES2535401T3 (es) | 2015-05-11 |
| BRPI0816144A2 (pt) | 2015-02-18 |
| RU2010110658A (ru) | 2011-09-27 |
| JP5404625B2 (ja) | 2014-02-05 |
| CN101854919B (zh) | 2012-02-15 |
| CN101854919A (zh) | 2010-10-06 |
| JP2010536837A (ja) | 2010-12-02 |
| GB0716591D0 (en) | 2007-10-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Luo et al. | Multifunctional role of polyvinylpyrrolidone in pharmaceutical formulations | |
| ES2399810T3 (es) | Forma de dosificación farmacéutica sólida que comprende una dispersión sólida de ritonavir y lopinavir | |
| ES2409055T3 (es) | Sistema de suministro de fármacos que comprende polioxazolina y un agente bioactivo | |
| US10632074B2 (en) | Composite granulated product including sugar or sugar alcohol, swelling binder, disintegrating agent and highly absorbent excipient, and method for manufacturing composite granulated product | |
| EP3076951B1 (en) | Process for the production of drug formulations for oral administration | |
| US8053000B2 (en) | Compositions for drug delivery | |
| RU2435592C2 (ru) | Композиция пролекарства для борьбы с вирусом гепатита с | |
| CA2976811A1 (en) | Solid dispersions of ospemifene | |
| CN104352482A (zh) | 膜组合物 | |
| ES3055123T3 (en) | Pharmaceutical composition comprising enzalutamide | |
| ES3018260T3 (en) | Method for producing an apixaban granulate | |
| WO2015030854A1 (en) | Solid dispersion formulation of an antiviral compound | |
| JP2019519570A5 (enExample) | ||
| JP2010536837A5 (enExample) | ||
| JP2019524724A (ja) | テコビリマットの経口用医薬組成物及びその調製法 | |
| Kumari et al. | Paramount role of solid dispersion in enhancement of solubility | |
| KR101478779B1 (ko) | 재수화시간이 향상된 택산 유도체 함유 동결건조 조성물 및이의 제조방법 | |
| Obaidat et al. | Effect of different polymeric dispersions on in-vitro dissolution rate and stability of celecoxib class II drug | |
| DK1968638T3 (en) | Controlled release gels | |
| WO2017155020A1 (ja) | 微細粒子含有組成物およびその製法 | |
| JP6666352B2 (ja) | デュタステリド含有固体分散体及びこれを含む組成物 | |
| CN101827584A (zh) | N-芳基脲基药物的固态分散体产品 | |
| WO2014041489A2 (en) | Pharmaceutical dosage form | |
| JP2012500788A5 (enExample) | ||
| Mogoşanu et al. | Pharmaceutical natural polymers: structure and chemistry |